AR and prostate cancer: However recent studies documented that the cannabinoids CBD was able to reduce androgen receptor (AR)-positive (LNCaP and 22RV1) and AR-negative (DU-145 and PC-3) cells in a CB receptors independent manner [202], suggesting that CB1 receptor could be the main cannabinoid receptor that regulates the complex carcinogenic steps leading to prostate cancer.